Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07223658 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | PHASE1 | RECRUITING | 78 | — | — | Dec 22, 2025 | Jul 1, 2027 | Jan 9, 2026 | 1 | New Zealand |
| Arm | Type | Description |
|---|---|---|
| ARO-DIMERPA | EXPERIMENTAL | ARO-DIMERPA in single or multiple ascending doses |
| Placebo | PLACEBO_COMPARATOR | Placebo (normal saline, 0.9%) in single or multiple matching doses |
| Name | Type | Description |
|---|---|---|
| ARO-DIMERPA | DRUG | Subcutaneous (SC) injection |
| Placebo | DRUG | Calculated volume to match active treatment by SC injection |
Inclusion Criteria: * Willing to follow diet counseling as per Investigator judgment based on local standard of care * Specific fasting TG, LDL-C, and non-high density lipoprotein cholesterol levels at Screening * Participants of childbearing potential must agree to use highly effective contracepti...